Please login to the form below
ViroPharma
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of ViroPharma's 2013 immunology sales performance.
Nabriva Therapeutics appoints chief medical officer
Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
Merck says drug for CMV in transplant patients hits targets
phase III testing that it acquired along with ViroPharma in 2013.
FDA grants fast track designation to Shire’s Cinryze
At the end of 2013, Shire signed a deal with US company Viropharma for around $4.2bn which gave the company rights to Cinryze.
Pharma deals in August 2015
indication]. Interestingly, the right to make the Meritage acquisition came via the purchase of ViroPharma.
Medius Deal Watch table for February 2015
Turkey. † US. †† Financial details source - Viropharma's 2013 Consolidated Financial Statement. .
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Weber Shandwick
At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
